All In Biotech

Drug Trial Radar · NCT04736173

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Feb 8, 2021

Primary completion

Sep 17, 2026

Study completion Sep 17, 2026

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Feb 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer
  • Nonsquamous Non Small Cell Lung Cancer
  • Squamous Non Small Cell Lung Cancer
  • Lung Cancer

Interventions

  • DomvanalimabDrug

    Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

  • ZimberelimabDrug

    Zimberelimab is a fully human anti-PD-1 monoclonal antibody

  • CarboplatinDrug

    Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • PaclitaxelDrug

    Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • PemetrexedDrug

    Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

  • PembrolizumabDrug

    Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: From randomization until death from any cause (up to 7 years)

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Columbus, Georgia

  • Research Site

    Kingwood, Texas

  • Research Site

    Blacksburg, Virginia

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Johor Bahru, Malaysia

  • Research Site

    Kuala Lumpur, Malaysia

  • Research Site

    Kuantan, Malaysia

  • Research Site

    Kuching, Malaysia

  • Research Site

    Pulau Pinang, Malaysia

  • Research Site

    Putrajaya, Malaysia

  • Research Site

    Davao City, Philippines

  • Research Site

    Manila, Philippines

  • Research Site

    George, South Africa

  • Research Site

    Johannesburg, South Africa

  • Research Site

    Pretoria, South Africa

  • Research Site

    Daegu, South Korea

  • Research Site

    Incheon, South Korea

  • Research Site

    Jinju, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Suwon, South Korea

  • Research Site

    Taichung, Taiwan

  • Research Site

    Bangkok, Thailand

  • Research Site

    Changwat Sara Buri, Thailand

  • Research Site

    Chanthaburi, Thailand

  • Research Site

    Chiang Mai, Thailand

  • Research Site

    Khon Kaen, Thailand

  • Research Site

    Lampang, Thailand

  • Research Site

    Nakhon Nayok, Thailand

  • Research Site

    Nakhon Ratchasima, Thailand

  • Research Site

    Phitsanulok, Thailand

  • Research Site

    Songkhla, Thailand

  • Research Site

    Ubon Ratchathani, Thailand

  • Research Site

    Adana, Turkey (Türkiye)

  • Research Site

    Ankara, Turkey (Türkiye)

  • Research Site

    Edirne, Turkey (Türkiye)

  • Research Site

    Istanbul, Turkey (Türkiye)

  • Research Site

    Kocaeli, Turkey (Türkiye)

  • Research Site

    Hanoi, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.